⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9860256 | 0.93 | — | — | |
| SCHEMBL169881 | 0.91 | — | — | |
| SCHEMBL4407106 | 0.84 | — | — | |
| SCHEMBL8518192 | 0.78 | — | — | |
| SCHEMBL10944262 | 0.71 | — | — | |
| SCHEMBL6811753 | 0.70 | KDM1A (0.34) | — | |
| SCHEMBL19003295 | 0.70 | KDM4E (0.31) | — | |
| SCHEMBL486040 | 0.69 | TLR4 (0.35) | — | |
| SCHEMBL8750616 | 0.68 | — | — | |
| SCHEMBL5880908 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250302827-A1 | Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto | UNIV EMORY (US) | 2025-10-02 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-12357629-B2 | Uses of BCL-2 antagonists for treating cancer and diagnostics related thereto | EMORY UNIVERSITY (US) | 2025-07-15 | — | — | US | disclosed |
| CN-115991678-B | Diketopiperazine compound, preparation method and application thereof | 上海惠永药物研究有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-113527217-B | Diketopiperazine compound and application thereof | 上海惠永药物研究有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-113527216-B | Preparation method of diketopiperazine compound, intermediate thereof and preparation method thereof | 上海惠永药物研究有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| US-20060148867-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
| WO-2006065484-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065646-A1 | BENZISOTHIAZOLE-1, 1-DIOXIDE ACTING AS ANTAGONISTS TO THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES | 2006-06-15 | — | — | US | disclosed |
| WO-2006062981-A2 | ANTAGONISTS TO THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-15 | — | — | WO | disclosed |
| US-5859042-A | ALOPECIA, ACNE, DISEASES OF THE PROSTATE GLANDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0783488-A4 | FIVE MEMBERED HETEROCYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0783488-A1 | FIVE MEMBERED HETEROCYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010013-A1 | FIVE MEMBERED HETEROCYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-04-04 | — | — | WO | disclosed |